Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Inventiva S.A.

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.

AbbVie

European Investment Bank

Sofinnova Partners

Novo Holdings

BVF Partners

New Enterprise Associates

Biotechnology Value Fund

Inventiva Pharma

#PressRelease: Inventiva reports preliminary 2023 fiscal year financial information and provides an update on its clinical trial NATiV3

To learn more, visit https://lnkd.in/eY6YRZtn

#PressRelease: Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

To learn more, visit: https://lnkd.in/eY6YRZtn

#PressRelease: Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

To learn more, visit: https://lnkd.in/eY6YRZtn

We're excited to share that Inventiva’s leadership team is attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 8-11, 2024. We look forward to connecting with global industry leaders, emerging companies, and the investment community. 

Learn more: https://lnkd.in/eZBPTdbM

EURONEXT:IVA

Inventiva Pharma

Last Close

2.21

26/07 15:35

Market Cap

125.95M

Beta: 1.22

Volume Today

86.85K

Avg: 62.36K

PE Ratio

−2.63

PFCF: −3.95